News - Pharmaceutical, Asia-Pacific, Gastro-intestinals

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

29-03-2014

Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion…

Asia-PacificGastro-intestinalsJapanLicensingMarkets & MarketingOtsukaPharmaceuticalTAK-438Takeda Pharmaceuticalsvonoprazan

Latest Australian PBS Listings include medicines for children

Latest Australian PBS Listings include medicines for children

19-03-2014

Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be…

Anti-Arthritics/RheumaticsAsia-PacificAustraliaDermatologicalsDiabetesGastro-intestinalsHealthcareOncologyPharmaceuticalPricing

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

15-01-2014

Japanese drug major Astellas Pharma and partner UMN Pharma have announced promising summary results for…

Asia-PacificASP7374Astellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceuticalResearchUMN PharmaVaccines

Takeda's vedolizumab enters Ph III in Japan for UC and Crohn's disease

Takeda's vedolizumab enters Ph III in Japan for UC and Crohn's disease

08-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical revealed today that vedolizumab), an investigational…

Asia-PacificGastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Eisai expands marketing and supply agreement for Belviq worldwide

Eisai expands marketing and supply agreement for Belviq worldwide

08-11-2013

Japanese drug major Eisai (TYO: 4523) has expanded the marketing and supply agreement between its US…

Asia-PacificBelviqEisaiGastro-intestinalsLicensingPharmaceutical

PeptiDream and Ipsen expand their peptide drug collaboration to treat endocrinologic disease

07-10-2013

PeptiDream and Ipsen have expanded the scope of their April 2013 research collaboration and license option…

Asia-PacificGastro-intestinalsIpsenLicensingPeptiDreamPharmaceutical

Astellas gains marketing approval for Irribow

16-08-2013

Japanese drug major Astellas Pharma (TYO: 4503) has gained marketing approval in Japan for Irribow (ramosetron…

Asia-PacificAstellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceutical

Japanese launches of subcutaneous injection forms of Pralia and Enbrel, and of Acofide

11-06-2013

Among a bunch of Japanese drug launches in the past couple of days, Daiichi Sankyo (TYO: 4568) announced…

AcofideAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaDaiichi SankyodenosumabEnbrelGastro-intestinalsMarkets & MarketingPfizerPharmaceuticalPraliaTakeda PharmaceuticalsZeria Pharmaceuticals

FDA approves Eisai's Aciphex Sprinkle for GERD in children; Inovelon OKed in Japan

28-03-2013

Japanese drug major Eisai (TYO: 4523) says that the US Food and Drug Administration has approved Aciphex…

AciphexAsia-PacificEisaiGastro-intestinalsInovelonNeurologicalNorth AmericaPharmaceuticalRegulation

Zeria and Astellas' Acofide approved in Japan for functional dyspepsia

27-03-2013

Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the marketing of Acofide (acotiamide…

AcofideAsia-PacificAstellas PharmaGastro-intestinalsPharmaceuticalRegulationZeria Pharmaceuticals

Kyowa Hakko and Astellas get new indication for Pasetocin and Sawacillin; latter applies for new Dormicum use

21-02-2013

Japanese drug major Kyowa Hakko Kirin (TYO: 4151) and Astellas Pharma (TYO: 4503) have jointly announced…

Asia-PacificAstellas PharmaDormicumGastro-intestinalsKyowa Hakko KirinNeurologicalPasetocinPharmaceuticalRegulationSawacillin

Abbott launches Sucampo's Amitiza in Japan

27-11-2012

US drugmaker Sucampo Pharmaceuticals (Nasdaq: SCMP), and marketing partner health care major Abbott Laboratories…

Abbott LaboratoriesAmitizaAsia-PacificGastro-intestinalsMarkets & MarketingPharmaceuticalSucampo

AstraZeneca gains rights to sell Ironwood's IBS drug in China

24-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an agreement with the USA's Ironwood…

Asia-PacificAstraZenecaGastro-intestinalsIronwood PharmaceuticalsLicensinglinaclotideMarkets & MarketingNexiumNorth AmericaPharmaceutical

Pharmaceutical majors unite in Japan to combat H. pylori

18-09-2012

On August 31, nine pharmaceutical companies operating in Japan (Kyowa Hakko Kirin, Takeda Pharmaceutical,…

Antibiotics and Infectious diseasesAsia-PacificAstraZenecaGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

Regulatory briefs: Amitiza in Japan; Dificid in Canada; Eurartesim roll-out

06-07-2012

Sucampo Pharmaceuticals (Nasdaq: SCMP) and Abbott Labs (NYSE: ABT) have received approval from the Ministry…

Abbott LaboratoriesAmitizaAntibiotics and Infectious diseasesAsia-PacificDificidEurartesimGastro-intestinalsMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulationSigma-TauSucampoTropical diseases

Nycomed to market Almirall’s Kestine in Southeast Asia markets; files for linaclotide in EU

30-09-2011

Swiss drug maker Nycomed, currently the subject of a 9.6 billion-euro takeover by Japan’s Takeda…

AlmirallAsia-PacificEuropeGastro-intestinalsLicensinglinaclotideNycomedPharmaceuticalRegulationRespiratory and Pulmonary

Abbott and Eisai launch of PDER drug Lipacreon in Japan

31-08-2011

Following regulatory approval earlier this year (The Pharma Letter April 27), the Japanese subsidiary…

Abbott LaboratoriesAsia-PacificEisaiGastro-intestinalsLipacreonMarkets & MarketingPharmaceutical

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top